TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.10 per share (TEVA)

Historical Holders from Q1 2014 to Q3 2025

Symbol
TEVA on NYSE
CUSIP
881624209
Type / Class
Equity / Ordinary Shares, par value NIS 0.10 per share
Shares outstanding
1.15B
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
656M
Holdings value
$13.2B
% of all portfolios
0.022%
Grand Portfolio weight change
-0.002%
Number of holders
526
Number of buys
242
Number of sells
-230
Average Value change %
-0.01%
Average buys %
+0.003%
Average sells %
-0.015%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.10 per share (TEVA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MENORA MIVTACHIM HOLDINGS LTD. 5% $1B 57.4M Menora Mivtachim Holdings Ltd Jul 16, 2025
Phoenix Financial Ltd. 5% $1B 57.4M Phoenix Financial Ltd. Jul 14, 2025

Institutional Holders of TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.10 per share (TEVA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 656M $13.2B -$1.07B $20.20 526
2025 Q2 712M $11.9B +$35.7M $16.76 530
2025 Q1 711M $10.9B +$519M $15.37 551
2024 Q4 666M $14.7B +$851M $22.04 568
2024 Q3 619M $11.2B +$273M $18.02 537
2024 Q2 609M $9.89B +$636M $16.25 527
2024 Q1 571M $8.05B -$17.5M $14.11 477
2023 Q4 351K $3.67M -$1.83M $10.44 5
2023 Q3 553M $5.64B +$724M $10.20 419
2023 Q2 483M $3.64B -$709M $7.53 410
2023 Q1 552M $4.88B -$28.5M $8.85 421
2022 Q4 545M $4.97B +$2.42M $9.12 405
2022 Q3 559M $4.5B +$430M $8.07 384
2022 Q2 493M $3.71B -$46.3M $7.52 414
2022 Q1 507M $4.76B +$104M $9.39 412
2021 Q4 496M $3.97B -$264M $8.01 393
2021 Q3 519M $5.06B -$346M $9.74 404
2021 Q2 556M $5.5B -$134M $9.90 418
2021 Q1 568M $6.55B +$15.1M $11.54 427
2020 Q4 558M $5.38B +$54.4M $9.65 410
2020 Q3 562M $5.06B -$193M $9.01 412
2020 Q2 563M $6.93B +$316M $12.33 425
2020 Q1 549M $4.93B -$448M $8.98 423
2019 Q4 583M $5.72B -$12.6M $9.80 392
2019 Q3 584M $4.02B -$352M $6.88 373
2019 Q2 635M $5.86B -$327M $9.23 428
2019 Q1 667M $10.4B -$208M $15.68 488
2018 Q4 679M $10.5B +$639M $15.42 512
2018 Q3 636M $13.7B -$673M $21.54 539
2018 Q2 667M $16.2B +$160M $24.32 520
2018 Q1 664M $11.3B +$1.3B $17.09 487
2017 Q4 583M $11B +$1.03B $18.95 485
2017 Q3 531M $9.34B -$1.11B $17.60 511
2017 Q2 586M $19.4B +$410M $33.22 638
2017 Q1 575M $18.4B +$209M $32.09 677
2016 Q4 595M $21.6B +$595M $36.25 718
2016 Q3 567M $26.1B -$1.24B $46.01 782
2016 Q2 595M $29.9B -$270M $50.23 800
2016 Q1 596M $31.9B -$699M $53.51 825
2015 Q4 610M $40B +$4.9B $65.64 866
2015 Q3 519M $29.3B +$629M $56.46 805
2015 Q2 512M $30.3B -$367M $59.10 807
2015 Q1 522M $32.5B +$494M $62.30 815
2014 Q4 517M $29.7B +$654M $57.51 811
2014 Q3 500M $26.8B +$670M $53.75 761
2014 Q2 487M $25.5B +$774M $52.42 768
2014 Q1 472M $24.9B +$989M $52.84 762